Loading…
← CockpitCompetitor Analysis › 600422.SS KPC Pharmaceuticals, Inc. Class AOpen in the cockpit ↗

KPC Pharmaceuticals, Inc. Class A600422.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 80
Mkt cap
$940M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$10.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-8.0 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
121 days
19 Mar 2027
Close · CNYCN¥8.29
1D-2.1%
1W-4.5%
1M-4.3%
3M-9.1%
6M-6.4%
YTD-34.0%
1Y-38.8%
ATR %2.8%
52w lowhigh41.0% off high

What KPC Pharmaceuticals does

Employees: 5,072

KPC Pharmaceuticals at a glance

Size KPC Pharmaceuticals (600422.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $940M, the 2272nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.29 on 18 Nov 2026.

Performance Over six months the shares fell 6.4%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 40.8% over the last twelve months (peer median +2.4%); the operating margin is -10.5% (peer median 8.8%).

Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.5× (2nd cheapest of 18).

Capital Return on invested capital runs 8.0 points below its cost of capital (5.0% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026600422.SS 96Peer median 79
Six months, rebased to 100: KPC Pharmaceuticals against the median of its 20 peers (local-currency closes).

KPC Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.55BCN¥6.54BCN¥8.34BCN¥8.37BCN¥8.23B
Revenue growth—-22%0%+2%—
Gross profitCN¥1.31BCN¥2.38BCN¥3.48BCN¥3.77BCN¥3.26B
EBITDAn/aCN¥442MCN¥1.01BCN¥900MCN¥675M
Net income-CN¥285MCN¥350MCN¥648MCN¥541MCN¥383M
Free cash flow-CN¥676MCN¥229MCN¥744MCN¥660MCN¥161M
Capital expenditureCN¥126MCN¥90.6MCN¥79.4MCN¥110MCN¥102M
Total debtCN¥1.82BCN¥2.11BCN¥1.45BCN¥1.21BCN¥1.43B

Quarterly statements and history in the cockpit →

KPC Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%002437600252603538STAR20056881770392003004013002941795688759MLTXIMTX25954565688553PGHLSPTX688382600422.SS6-month return →1-month return →
Up and to the right = strong over both horizons. KPC Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×25×50×75×0024376002526035386881770392001795IMTX2595688382600422.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. KPC Pharmaceuticals is the large dot.

KPC Pharmaceuticals competitors and peer comparison

How KPC Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

KPC Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure600422.SSPeer medianRank in peer set
1-month return-4.3%-10.1%4th highest of 21
6-month return-6.4%-22.0%5th highest of 21
Distance from 52-week high-41.0%-46.9%7th highest of 21
Revenue growth (TTM)-40.8%+2.4%5th lowest of 18
Operating margin-10.5%8.8%7th lowest of 18
EV / Sales1.8×4.5×2nd cheapest of 18
ROIC minus cost of capital-8.0 pp-2.0 pp5th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%

Questions

Which companies are KPC Pharmaceuticals's closest peers?
The cockpit's peer set: Harbin Gloria Pharmaceuticals (002437.SZ), Guangxi Wuzhou Zhongheng (600252.SS), Ningbo Menovo Pharmaceutical (603538.SS), Strides Pharma Science (STAR.NS), SSY (2005.HK), Bio-Thera Solutions (688177.SS), Oscotec (039200.KS), Zhejiang Garden Biopharmaceutical (300401.SZ).
Is KPC Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 1.8× against a peer median of 4.5×, 2nd cheapest of 18 in its peer set.
How has KPC Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -6.4% against -22.0% for the median peer; over one year -38.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.